Eric Bjerkholt Sells 6,001 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Posted by Francis Steltz on Aug 14th, 2026

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) CFO Eric Bjerkholt sold 6,001 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $99.90, for a total transaction of $599,499.90. Following the completion of the sale, the chief financial officer owned 36,355 shares of the company’s stock, valued at $3,631,864.50. This trade represents a 14.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eric Bjerkholt also recently made the following trade(s):

On Monday, July 6th, Eric Bjerkholt sold 5,000 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $122.25, for a total transaction of $611,250.00.
On Monday, June 8th, Eric Bjerkholt sold 5,000 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $93.82, for a total transaction of $469,100.00.

Mirum Pharmaceuticals Stock Down 0.2%

MIRM stock opened at $98.77 on Friday. The firm has a market cap of $6.41 billion, a PE ratio of -6.79 and a beta of 0.52. Mirum Pharmaceuticals, Inc. has a 1 year low of $63.23 and a 1 year high of $130.00. The company has a fifty day simple moving average of $110.77 and a 200 day simple moving average of $102.00. The company has a current ratio of 2.86, a quick ratio of 2.74 and a debt-to-equity ratio of 1.28.

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The business had revenue of $176.24 million for the quarter, compared to analyst estimates of $166.33 million. During the same period in the previous year, the company earned ($0.12) earnings per share. The company’s quarterly revenue was up 37.9% compared to the same quarter last year. Sell-side analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.31 EPS for the current fiscal year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP bought a new stake in shares of Mirum Pharmaceuticals in the 2nd quarter worth approximately $44,000. Cullen Frost Bankers Inc. acquired a new position in shares of Mirum Pharmaceuticals in the fourth quarter valued at $30,000. Eurizon Capital SGR S.p.A. bought a new position in Mirum Pharmaceuticals in the fourth quarter worth $32,000. CIBC Private Wealth Group LLC bought a new position in Mirum Pharmaceuticals in the fourth quarter worth $32,000. Finally, State of Wyoming acquired a new stake in Mirum Pharmaceuticals during the second quarter worth $52,000.

Analysts Set New Price Targets

A number of brokerages recently weighed in on MIRM. Stifel Nicolaus set a $136.00 price objective on Mirum Pharmaceuticals in a research note on Thursday, May 7th. CLSA set a $146.00 price target on Mirum Pharmaceuticals in a report on Monday, June 15th. Citigroup reissued an “outperform” rating on shares of Mirum Pharmaceuticals in a research report on Thursday, August 6th. Evercore reissued an “outperform” rating and issued a $138.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. Finally, Citizens Jmp reduced their price objective on shares of Mirum Pharmaceuticals from $146.00 to $137.00 and set a “market outperform” rating for the company in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $137.33.

Check Out Our Latest Report on Mirum Pharmaceuticals

Mirum Pharmaceuticals Company Profile

(Get Free Report)

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.